INTRODUCING THE DEEPCHEK GENOTYPING TECHNOLOGY OVERVIEW & USERS EXPERIENCE Webinar from Tuesday January 30, 2024 – 4pm CET Revue de la Solution DeepChek Genotyping à travers un Webinaire présenté par notre équipe et par un panel d’experts :
ABL Diagnostics Webinar Series – Session II Read More »
REVUE DE LA TECHNOLOGIE DE GENOTYPAGE DEEPCHEK PRESENTATION & EXPERIENCES UTILISATEUR Webinaire réalisé le mardi 23 janvier 2024 – 10h00 CET Revue de la Solution DeepChek Genotyping à travers un Webinaire présenté par notre équipe et par un panel d’experts :
ABL Diagnostics Webinar Series Read More »
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the release of its DeepChek®-HPV Assay for the screening, the genotyping, and the discrimination of the Human Papillomavirus (“HPV”). The assay uses an innovative design which allows
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the release of new versions of its CE-IVD (In Vitro Diagnostics) DeepChek® and ViroScore® software applications (v3.30.115-ivdr). Tailored to analyze Next Generation Sequencing (NGS) and Capillary Electrophoresis
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce a major evolution of its research & development activities with the design of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology. With the intent
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce the expansion of its HIV genotyping menu of applications with the release of a new revolutionary assay, DeepChek® Assay HIV-1 Full PR/RT/INT Drug Resistance. The company keeps innovating
ABL DIAGNOSTICS EXPANDS ITS HIV GENOTYPING ASSAYS OFFERING Read More »
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the expansion of its network of exclusive distributors, able to offer the DeepChek® technology to laboratories willing to implement microbiology applications like HIV, SARS-CoV-2, Tuberculosis, Cytomegalovirus, Viral
DeepChek ® HCV / HBV / HDV Assays & Software Send Me More information
DeepChek ® HCV / HBV / HDV Assays & Software Read More »
New kit Available !! Genotyping of the Full HIV-1 pol Gene with PR+RT+INT Regions in One Single PCR Reaction Send Me More information
